Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

34.40 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Pacira Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 07, 2022

On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73.

Via Investor's Business Daily

Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment ↗

September 27, 2022

Via Benzinga

Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating ↗

September 23, 2022

Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.

Via Investor's Business Daily

Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

September 14, 2022

Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99.

Via Investor's Business Daily

Sage Therapeutics Stock Scores Relative Strength Rating Upgrade ↗

September 09, 2022

On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.

Via Investor's Business Daily

Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98 ↗

September 09, 2022

Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before.

Via Investor's Business Daily

HC Wainwright Is Bullish On This Multiple Myeloma Focused Stock ↗

August 22, 2022

Via Benzinga

Where Genmab Stands With Analysts ↗

August 11, 2022

Genmab (NASDAQ:GMAB) has observed the following analyst ratings within the last quarter:

Via Benzinga

Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates ↗

August 05, 2022

Via Benzinga

Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗

September 02, 2022

Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93.

Via Investor's Business Daily

Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

September 01, 2022

On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier.

Via Investor's Business Daily

Golden Cross Appears Before Genmab Investors ↗

August 31, 2022

If history is any guide, there may be good fortune ahead for shares of Genmab (NASDAQ:GMAB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...

Via Benzinga

Intercept Pharmaceutical Stock Shows Market Leadership; Earns 92 RS Rating ↗

August 30, 2022

On Tuesday, Intercept Pharmaceutical stock had its Relative Strength Rating upgraded to 92, up from 89 a day earlier.

Via Investor's Business Daily

Relay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating ↗

August 25, 2022

Relay Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 84 to 94.

Via Investor's Business Daily

Kymera Therapeutics Stock Scores Rising Relative Price Strength ↗

August 22, 2022

Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94.

Via Investor's Business Daily

Where Genmab Stands With Analysts ↗

June 24, 2022

Analysts have provided the following ratings for Genmab (NASDAQ:GMAB) within the last quarter:

Via Benzinga

AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial ↗

June 13, 2022

Via Benzinga

Analyst Ratings for Genmab ↗

May 12, 2022

Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings:

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

August 05, 2022

From Genmab A/S

Via Business Wire

AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022 ↗

July 18, 2022

Via Benzinga

Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

July 18, 2022

From Genmab A/S

Via Business Wire

Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom? ↗

July 07, 2022

Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.? Is AbbVie stock a buy today

Via Investor's Business Daily

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact ↗

July 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022 ↗

June 24, 2022

Upgrades

Via Benzinga

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

June 11, 2022

From Genmab

Via Business Wire

Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

June 06, 2022

From Seagen Inc.

Via Business Wire

Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

June 06, 2022

From Genmab A/S

Via Business Wire

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2022

From Genmab

Via Business Wire

Johnson & Johnson Stock: A Rare Bright Spot in the Market ↗

May 14, 2022

JNJ stock is up on the year thanks in part to its steadily rising dividend, which investors covet during the current market volatility.

Via InvestorPlace

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.